The good news: My Dad, after a scary health episode, is feeling better. The not-so-good news: The surveillance system for monitoring safety and effectiveness of marketed drugs is still broken. But there is hope.
Sarepta Therapeutics is one of those rare biotech stories with Hollywood appeal. Its CEO was ousted this week, and it may never deliver the happy ending so many desperate parents are counting on for children with Duchenne Muscular Dystrophy. But no matter what, the company has helped spark a renaissance of R&D for this crippling rare disease. To get a... Read More
Bacteria, when confronted with the same old antibiotics, find ways to survive and sometimes kill people. Drugmakers haven’t paid much attention in recent years. But now, after repeated warnings about the rise of drug-resistant bacteria and some new profit incentives, the industry is coming around to the fight against “superbugs.” Drugmakers have long seen bigger opportunities to make money elsewhere.... Read More
The one time I saw FDA commissioner Margaret Hamburg speak was memorable only for its dullness. Firebrand liberal Elizabeth Warren, the U.S. Senator from Massachusetts, woke everybody up before Hamburg put everyone to sleep. Nothing Hamburg said was even close to newsworthy. That sums up the brilliance of a public servant who will go down as one of the best food... Read More
This is the cold, dreary, snowy time of year when all the geeky kids in genomics flock to a remote island off the Florida Gulf Coast. The boys, and they are mostly boys, will hear a lot of marketing hype about the whiz-bang new tools being developed for biology. They’ll hear a few nitty-gritty technical talks from scientists doing exciting... Read More
Black people suffer from all kinds of health disparities compared with other racial and ethnic groups. Yet diseases that mainly hit African Americans seldom get to the top of the R&D priority list. Global Blood Therapeutics is one of the rare companies that could build a big business and put a dent in a stubborn societal problem.
One of the great talent migrations in pharmaceutical R&D history is going on right now. Merck, the drugmaker with a proud scientific tradition, has seen a huge wave of departures from its senior R&D ranks the past two years. The exodus has turned into a recruiting bonanza for a range of biotech startups, venture firms, consultancies, and competitors. The exits flung open... Read More
The Timmerman Report Gives You Consistent In-Depth Reporting on Biotechnology. Get Your Edge.